Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways

British Journal of Pharmacology
F Perez-VizcainoJ Tamargo

Abstract

1. The effects of the K+ channel opener levcromakalim, the guanylate cyclase stimulant nitroprusside and the dual drug nicorandil (K+ channel opener and guanylate cyclase stimulant) were analysed in piglet isolated endothelium-denuded pulmonary (PA) and mesenteric (MA) arteries stimulated by noradrenaline (NA) or by the thromboxane A2 mimetic U46619. 2. Nicorandil, levcromakalim and verapamil were less potent in PA than in MA, the efficacy of levcromakalim was also reduced in PA. The effects of nicorandil and levcromakalim were similar in arteries pre-contracted by NA and U46619, whereas verapamil was more potent in arteries pre-contracted by NA. Nitroprusside was equipotent in MA pre-contracted by either NA or U46619 and in PA pre-contracted by NA whereas in PA pre-contracted by U46619, nitroprusside showed lower potency and efficacy. 3. The relaxant effects of levcromakalim and nitroprusside were inhibited by 10(-5) M glibenclamide and 10(-6) M ODQ, respectively. Nicorandil-induced relaxation was inhibited by ODQ in all experimental conditions, whereas glibenclamide had inhibitory effects in PA and MA pre-contracted by U46619, had no effect in PA pre-contracted by NA and in MA pre-contracted by NA it was only inhibitory in th...Continue Reading

References

Aug 1, 1991·European Journal of Clinical Investigation·S Moncada, E A Higgs
Sep 1, 1990·Pflügers Archiv : European journal of physiology·B HimpensA P Somlyo
Jul 1, 1986·The Journal of Clinical Investigation·F Murad
Jan 1, 1985·Annual Review of Pharmacology and Toxicology·L J Ignarro, P J Kadowitz
Apr 1, 1995·The American Journal of Physiology·M T Nelson, J M Quayle
Sep 1, 1993·Trends in Pharmacological Sciences·U Quast
Jan 1, 1993·Annual Review of Pharmacology and Toxicology·G Edwards, A H Weston

❮ Previous
Next ❯

Citations

May 26, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Naoto OgawaKunio Ishii
Dec 22, 1999·British Journal of Pharmacology·F Pérez-VizcaínoJ Tamargo
Jun 2, 2009·Journal of Ethnopharmacology·Oluwatosin A AdaramoyeIsac A Medeiros
Apr 9, 2015·Journal of Pharmacological Sciences·Marija MarinkoGuo-Wei He
Jan 24, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Rachel Melo RibeiroMarilene Oliveira da Rocha Borges
Oct 13, 2010·Journal of Ethnopharmacology·Roseli SonciniAlexandre Giusti-Paiva
Apr 19, 2012·Journal of Pharmacological Sciences·Zhan-Qing WangMing Zeng
Mar 14, 2017·Clinical and Experimental Hypertension : CHE·G Sargazi Zadeh, N Panahi
Nov 24, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·D N GuedesI A Medeiros
Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Ruth WeissHansjörg Danuser
Sep 13, 2002·American Journal of Physiology. Lung Cellular and Molecular Physiology·Francisco Pérez-VizcaínoJuan Tamargo
Dec 8, 2011·Journal of Cardiovascular Pharmacology·Aleksandra NovakovicGuo-Wei He

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.